Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
12.35
-0.16 (-1.28%)
At close: Jan 22, 2026, 4:00 PM EST
12.35
0.00 (0.00%)
After-hours: Jan 22, 2026, 4:00 PM EST
Tango Therapeutics Employees
Tango Therapeutics had 155 employees as of December 31, 2024. The number of employees increased by 15 or 10.71% compared to the previous year.
Employees
155
Change (1Y)
15
Growth (1Y)
10.71%
Revenue / Employee
$429,039
Profits / Employee
-$648,484
Market Cap
1.66B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 155 | 15 | 10.71% |
| Dec 31, 2023 | 140 | 30 | 27.27% |
| Dec 31, 2022 | 110 | 19 | 20.88% |
| Dec 31, 2021 | 91 | 14 | 18.18% |
| Dec 31, 2020 | 77 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 488 |
| Intellia Therapeutics | 403 |
| Precigen | 143 |
| Stoke Therapeutics | 128 |
| Kodiak Sciences | 123 |
| Definium Therapeutics | 74 |
| Enliven Therapeutics | 62 |
| RAPT Therapeutics | 60 |
TNGX News
- 8 days ago - Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - GlobeNewsWire
- 17 days ago - Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewsWire
- 5 weeks ago - Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy - Seeking Alpha
- 3 months ago - Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript - Seeking Alpha
- 3 months ago - Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement - Benzinga